ePrivacy and GPDR Cookie Consent by Cookie Consent

DRUG TARGETS: NTRK - The UK regulator NICE has approved the use of larotrectinib for patients with advanced NTRK fusion position solid tumours, in both adults and children.


April 27, 2020


Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229]<wbr></wbr> Expected publication date:

To appraise the clinical and cost effectiveness of larotrectinib within its marketing authorisation for treating NTRK fusion-positive advanced solid tumours.
Status In progress
Process STA 2018
ID number 1299

Provisional Schedule

Final appraisal document 21 April 2020 - 06 May 2020
Expected publication 27 May 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors Bayer
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups GIST Support UK
  Roy Castle Lung Cancer Foundation
  Sarcoma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Society and College of Radiographers


Comparator companies Janssen-Cilag Ltd
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
03 April 2020 Committee meeting: 2
04 March 2020 Committee meeting: 2
17 January 2020 - 07 February 2020 Appraisal consultation
20 November 2019 Committee meeting
20 March 2019 Invitation to participate
16 October 2018 This appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorisation. The appraisal is now anticipated to begin during early April 2019.
20 September 2018 (10:00) Scoping workshop (London)
19 July 2018 - 16 August 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance